Laboratory for Molecular Genetics, Centre for Medical Research, QEII Medical Centre, University of Western Australia, Perth, Western Australia, Australia.
Eur J Hum Genet. 2011 Mar;19(3):326-33. doi: 10.1038/ejhg.2010.181. Epub 2010 Nov 17.
Primary congenital glaucoma (PCG) is a genetically heterogeneous autosomal recessive disorder, which is an important cause of blindness in childhood. The first known gene, CYP1B1, accounts for a variable proportion of cases in most populations. A second gene, LTBP2, was recently reported in association with a syndrome, in which glaucoma is secondary to lens dislocation. We report on the molecular and clinical profile of 34 families diagnosed as PCG, all originating from the Roma/Gypsy founder population. Comprehensive sequencing analysis revealed a level of heterogeneity unusual for this population, with five CYP1B1 and one ancestral LTBP2 mutation accounting for ∼70% of patients (25 out of 37) and the remainder still unexplained. Homozygosity for the founder LTBP2 p.R299X mutation resulted in a more severe clinical phenotype and poorer outcome despite a markedly higher number of surgical interventions. The genetically homogeneous group of p.R299X homozygotes showed variable phenotypes (presumably also underlying pathogenetic mechanisms), wherein PCG proper with primary dysgenesis of the trabecular meshwork, and Marfan syndrome-like zonular disease with ectopia lentis and later onset secondary glaucoma are two extremes. The spectrum manifestations may occur in different combinations and have a different evolution even within the same sibship or a single patient. Preliminary observations on compounds with mutations in both CYP1B1-LTBP2 suggest that the observed combinations are of no clinical significance and digenic inheritance is unlikely. We provide a population genetics perspective to explain the allelic heterogeneity, comparing the history and geographic distribution of the two major founder mutations--p.R299X/LTBP2 and p.E387K/CYP1B1.
原发性先天性青光眼 (PCG) 是一种遗传异质性常染色体隐性疾病,是儿童失明的重要原因。第一个已知的基因 CYP1B1 占大多数人群中多种病例的可变比例。最近报道了第二个基因 LTBP2 与一种综合征相关,其中青光眼继发于晶状体脱位。我们报告了 34 个被诊断为 PCG 的家族的分子和临床特征,这些家族均源自罗姆/吉普赛创始人群体。综合测序分析显示,该人群的异质性程度异常,其中 5 个 CYP1B1 和 1 个祖先 LTBP2 突变占约 70%的患者(37 名患者中的 25 名),其余仍未得到解释。尽管进行了明显更多的手术干预,但 LTBP2 p.R299X 突变的纯合性导致更严重的临床表型和更差的结果。由于存在 founder LTBP2 p.R299X 突变的纯合性,导致了更严重的临床表型和更差的结果,尽管进行了明显更多的手术干预。纯合性 p.R299X 纯合子的遗传同质组显示出可变的表型(推测也存在潜在的发病机制),其中原发性小梁网发育不良的 PCG 以及 Marfan 综合征样的悬韧带疾病伴晶状体异位和后期发病的继发性青光眼是两个极端。在不同的组合中可能出现谱表现,甚至在同一兄弟姐妹或单个患者中也具有不同的演变。对 CYP1B1-LTBP2 突变的化合物的初步观察表明,观察到的组合没有临床意义,并且双基因遗传不太可能。我们从群体遗传学的角度来解释等位基因异质性,比较了两个主要的创始突变——p.R299X/LTBP2 和 p.E387K/CYP1B1 的历史和地理分布。